MRT-301

N/A

Report date: 2025/01/26 16:26:28

Base Information

Drug NameMRT-301
Drug Alias NameGrB-Fc-HMELAnti-GSPG4 granzyme B immunotherapy (Mirata BioPharma)Granzyme B -conjugated anti-chondroitin sulfate proteoglycan 4 synthetic antibody (Mirata BioPharma)Granzyme B -conjugated anti-melanoma gp240 antigen synthetic antibody (Mirata BioPharma)MRT-301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionChondroitin sulfate proteoglycan 4 modulators
TargetsChondroitin sulfate proteoglycan 4
Therapy Area/IndicationsBreast NeoplasmsMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesClayton Foundation For Research
China Registration ClassN/A

Develop Information

Active CompaniesMirata BioPharma Llc
Inactive CompaniesClayton Foundation For Research
Active IndicationsBreast NeoplasmsMelanoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A